More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated >

The concept of BBB penetration is anticipated to bring about a paradigm shift in modern healthcare. In fact, experts believe that there is an important relationship between the recent pandemic of Coronavirus disease (COVID-19) and cerebrovascular system, presenting commercial opportunities for players engaged in the development of BBB penetrating drugs.
 
To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this link 
 
The USD 940 million (by 2030) financial opportunity within the BBB market has been analyzed across the following segments:
Type of Payment Model Adopted
  • Upfront payments
  • Milestone payments
Type of Molecule
Small Molecules
Biologics
Target Disease Indication
  • Brain Metastases in Breast Cancer
  • Glioblastoma Multiforme
  • Hunter Syndrome
  • Hurler Syndrome
Leading Technology Platforms
  • G®-Technology
  • J-Brain Cargo® Technology
  • LRP-1 Technology
  • Trojan Horse Technology
Leading Drug Developers
  • 2-BBB
  • Angiochem
  • ArmaGen
  • JCR Pharmaceuticals
Key Geographical Regions
North America
Europe
Asia-Pacific


 
The Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics report features the following companies, which we identified to be key players in this domain: 
  • Angiochem
  • ArmaGen
  • BioArctic
  • Cyclenium Pharma
  • Denali Therapeutics
  • ICB International
  • Iproteos
  • JCR Pharmaceuticals
  • Lauren Sciences
  • Medesis Pharma
  • Ossianix
  • Vect-Horus
 
Table of Contents
 
1. Preface

2. Executive Summary

3. Introduction


4. Market Landscape: Non-Invasive BBB Penetration


5. Market Landscape: BBB Penetrating Drugs


6. Company Profiles


7. Technology Competitiveness Analysis


8. Non-Invasive BBB Penetration Technologies: Popular Approaches 

9. Partnerships and Collaborations


10. Analysis of Recent Licensing Agreements


11. Funding and Investment Analysis


12. Patent Analysis


13. Drug Development Strategy Analysis


14. Market Potential of Key Neurological Disorders 
15. Likely Partner Analysis
 
16. Market Forecast
 
17. Conclusion
 
18. Executive Insights
19. Appendix 1: Tabulated Data
20. Appendix 2: List of Companies and Organizations
 
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html
 
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected] 

You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
1311 Posts

Made with by Mamby